GV20-0251
Phase 2Small molecule
GV20-0251 is one of 104 small molecule programs targeting Refractory Solid Tumors. It is currently in Phase 2.
4
Indications
5
Total Trials
5
Active Trials
103
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
116 competitors in Head and Neck Squamous Cell Carcinoma
#DrugCompanyPhaseTrials
1Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Erbitux
IImclone
Phase 3
Beyfortus
BeiGenePhase 3
Imfinzi
AstraZenecaPhase 3
Ibrance
PfizerPhase 3
Taxotere
AAvyxa
Phase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 3
Gilotrif
Boehringer IngelheimPhase 3
Theraplaza
BBiotech Pharmaceutical Co., Ltd.
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Solid Tumor Malignancies2 trials
Head and Neck Squamous Cell Carcinoma1 trial
Rare Tumor1 trial
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
Not yet recruiting·—·Phase 1/2·NCT07307053·600 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GV20-0251. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- GGV20 Therapeutics